TriSalus Life Sciences insider awarded RSUs and stock options

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. (TLSI) reported equity awards to its Chief of Clinical Operations on a Form 4. The officer received 50,000 shares of common stock as a restricted stock unit (RSU) award on November 24, 2025, which will vest in four equal annual installments starting on that date, conditioned on continued employment at each vesting date.

The officer was also granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $5.55 per share. One-fourth of the option shares vest on the one-year anniversary of the November 24, 2025 vesting commencement date, and the remaining shares vest monthly in equal installments over the following three years, also subject to continued employment. Following these grants, the reporting person beneficially owned 100,571 shares of common stock directly and 463,750 derivative securities in the form of options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devlin Jodi

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER CO 80031

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Clinical Operations

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		A		50,000(1)	A	$0	100,571	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.55	11/24/2025		A		100,000		(2)	11/23/2025	Common Stock	100,000	$0	463,750	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date.

2. One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TriSalus Life Sciences (TLSI) report on this Form 4?

The filing reports equity awards to the Chief of Clinical Operations, including 50,000 RSUs and an option to purchase 100,000 shares of TLSI common stock granted on November 24, 2025.

How do the 50,000 TriSalus (TLSI) RSUs granted on November 24, 2025 vest?

The 50,000 RSUs vest in four equal annual installments starting on November 24, 2025, subject to the officer’s continued employment on each vesting date.

What are the terms of the 100,000-share stock option granted by TriSalus (TLSI)?

The employee stock option covers 100,000 shares of TLSI common stock at an exercise price of $5.55 per share. One-fourth of the shares vest on the one-year anniversary of November 24, 2025, and the remaining shares vest monthly in equal installments over the next three years, subject to continued employment.

How many TriSalus (TLSI) common shares does the reporting person own after these transactions?

After the reported transactions, the officer beneficially owned 100,571 shares of TLSI common stock directly.

How many derivative securities does the TriSalus (TLSI) insider hold after the option grant?

Following the option grant, the reporting person held 463,750 derivative securities, consisting of stock options relating to TLSI common stock.

Who is the reporting person and what is their role at TriSalus (TLSI)?

The reporting person is an officer of TriSalus Life Sciences, Inc., serving as Chief of Clinical Operations.